

Mr. Nick Sandberg  
c/o Relax UK Ltd  
31 D'arblay Street

London, W1V 3FG

Winfried Gerbracht  
Ertmanplatz 17  
D - 49082 Osnabrück  
Phone: 0049-541-571699

Winfried.Gerbracht@t-online.de

Oct. 07.2000

### Request for support

Ibopyrine – a cheap alternative

Dear Mr. Sandberg!

I am a german chemist, following the research of ibogaine since some years, from an idealistic standpoint. I am private and not associated with academia nor industry.

Ibogaine is an expensive compound, illegal in some countries and attached with some further problems.

I have got a good idea and outlined a synthesis for a series of new compounds on the basis of the iboga-structure, which I name IBOPYRINES. I designed them for to be safer, more effective, cheap (my estimation: less than 10 US Dollars a single dose) and of course legal. I contacted the only european chemical researcher dealing with ibogaine, Prof. Dr. Borschberg from the ETH in Zurich, and he offered me cooperation, so I am getting the chance to realize my synthetic project in his lab.

If it works, it will raise much benefit. It will definitely accelerate the exploration of the neurochemical mechanisms of antiaddiction!

This is a rare opportunity that I do not like to lose. The only weak point is, that Mr. Borschberg cannot give me any payment to cover the costs of living, my private resources are small and I doubt that there will be any funding for it, since I am an autodidact and thus in a certain way a hermit and not a person from the midst of the academic community, but money is a prerequisite, the success is mainly depending on a budget.

May I ask if you see any possibility for support, for example by promoting it by a public announcement?

I did not yet contacted Mr. Lotsof, since I am lacking his address.


Sincerely yours

Winfried




## Ibopyrine – cutting away the unessential

Since ibogaine is expensive, there is a great need to improve the economy. The answer lies simply in removing what's dispensable from the molecular structure. The overall structural profile is not affected by this step, the specific pharmacological action will remain the same. (This is called a bioisoster)



## Synthetic outline



## Web-page of Dr. Borschberg

<http://www.verw.ethz.ch/cgi-win/Who.exe?ID=444&lang=engl>



3D-Visualisation

IBOPYRINE

versus

IBOGAINE

